Trial Profile
Alimta (Pemetrexed) and Cisplatin Treatment as Neoadjuvant Therapy in Non Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Cisplatin; Dexamethasone; Folic acid
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 08 Apr 2022 This trial has been completed (End Date: 20 Dec 2007), according to European Clinical Trials Database record.
- 10 May 2011 New source identified and integrated (European Clinical Trials Database).
- 10 May 2011 Planned end date changed from 1 Aug 2010 to 21 Sep 2010 according to European Clinical Trials Database.